Details for: AIMOVIG
Company: NOVARTIS PHARMACEUTICALS CANADA INC
| DIN | DIN name | Active Ingredient(s) | Strength | Dosage Form | Route of Administration |
|---|---|---|---|---|---|
| 02479613 | AIMOVIG | ERENUMAB | 70 MG / ML | SOLUTION | SUBCUTANEOUS |
| 02487306 | AIMOVIG | ERENUMAB | 140 MG / ML | SOLUTION | SUBCUTANEOUS |
Summary Reports
Regulatory Decision Summary
Summary Safety Review - Aimovig (erenumab) - Assessing the Potential Risks of Non-Fatal Stroke, Non-Fatal Heart Attack and Cardiovascular Death
Summary Safety Review - Aimovig (erenumab) - Assessing the Potential Risks of Non-Fatal Stroke, Non-Fatal Heart Attack and Cardiovascular Death
Consumer Information
The Consumer Information is not yet available in the Drug and Health Product Register. Try searching on the active ingredient(s) to find other similar products.